Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;9(1):133–146. doi: 10.1111/j.1750-3639.1999.tb00215.x

Oxidative Alterations in Alzheimer's Disease

William R Markesbery 1,✉, John M Carney 2
PMCID: PMC8098393  PMID: 9989456

Abstract

There is increasing evidence that free radical damage to brain lipids, carbohydrates, proteins, and DNA is involved in neuron death in neurodegenerative disorders. The largest number of studies have been performed in Alzheimer's disease (AD) where there is considerable support for the oxidative stress hypothesis in the pathogenesis of neuron degeneration. In autopsied brain there is an increase in lipid peroxidation, a decline in polyunsaturated fatty acids (PUFA) and an increase in 4‐hydroxynonenal (HNE), a neurotoxic aldehyde product of PUFA oxidation. Increased protein oxidation and a marked decline in oxidative‐sensitive enzymes, glutamine synthetase and creatinine kinase, are found in the brain in AD. Increased DNA oxidation, especially 8‐hydroxy‐2′‐deoxyguanosine (8‐OHdG) is present in the brain in AD. Immunohistochemical studies show the presence of oxidative stress products in neurofibrillary tangles and senile plaques in AD. Markers of lipid peroxidation (HNE, isoprostanes) and DNA (8‐OHdG) are increased in CSF in AD. In addition, inflammatory response markers (the complement cascade, cytokines, acute phase reactants and proteases) are present in the brain in AD. These findings, coupled with epidemiologic studies showing that anti‐inflammatory agents slow the progression or delay the onset of AD, suggest that inflammation plays a role in AD. Overall these studies indicate that oxidative stress and the inflammatory cascade, working in concert, are important in the pathogenetic cascade of neurodegeneration in AD, suggesting that therapeutic efforts aimed at both of these mechanisms may be beneficial.

Full Text

The Full Text of this article is available as a PDF (120.6 KB).

References

  • 1. Aksenov MY, Aksenov MV, Payne RM, Smith CD, Markesbery WR, Carnay JM (1997) The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Exp Neurol 146: 458–465. [DOI] [PubMed] [Google Scholar]
  • 2. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR (1998) The expression of key oxidative stress handling genes in different brain regions in Alzheimer's disease. Accepted J Mol Neurosci . [DOI] [PubMed]
  • 3. Ames BN, Shigenaga MK, Hagen TM (1995) Mitochondrial decay in aging. Biochem Biophys Acta 1271:165–170. [DOI] [PubMed] [Google Scholar]
  • 4. Balazs L, Leon M (1994) Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19: 1131. [DOI] [PubMed] [Google Scholar]
  • 5. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7: 111–118. [DOI] [PubMed] [Google Scholar]
  • 6. Bauer MKA, Lieb K, Schulze‐Osthoff K, Berger, M , Gebicke‐Haerter PJ, Bauer J, Fiebich BL (1997) Expression and regulation of cyclooxygenase‐2 in rat microglia. Eur J Biochem 243: 726–731. [DOI] [PubMed] [Google Scholar]
  • 7. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357–366. [DOI] [PubMed] [Google Scholar]
  • 8. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson BJ, Bassett SS, Mclnnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha‐2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19: 357–360. [DOI] [PubMed] [Google Scholar]
  • 9. Blanc EM, Kelly JF, Mark RJ, Waeg G, Mattson MP (1997) 4‐Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha (q/11). J Neurochem 69: 570–580. [DOI] [PubMed] [Google Scholar]
  • 10. Braughler JM, Hall ED (1989) Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 6: 289–301. [DOI] [PubMed] [Google Scholar]
  • 11. Bredt DS, Snyder SH (1994) Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63: 175–195. [DOI] [PubMed] [Google Scholar]
  • 12. Brett J, Schmidt A. M., Yan SD, Zou Y‐S, Weidman E, Pinsky D, Nowgrod R, Neeper M, Przysiecki C, Shaw AEA (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699–1712. [PMC free article] [PubMed] [Google Scholar]
  • 13. Bruce‐Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP (1998) 4‐Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathol Exp Neurol 57: 257–267. [DOI] [PubMed] [Google Scholar]
  • 14. Burbaeva GS, Aksenova MV, Makarenko IG (1992) Decreased level of creatine kinases BB in the frontal cortex of Alzheimer patients. Dementia 3: 91–94. [Google Scholar]
  • 15. Carpenter AF, Carpenter PW, Markesbery WR (1993) Morphometric analysis of microglia in Alzheimer's disease. J Neuropathol Exp Neurol 52: 601–608. [DOI] [PubMed] [Google Scholar]
  • 16. Castellani, Smith MA (1998) Iron regulatory proteins in Alzheimer's disease. J Neuropathol Exp Neurol 51: 511. [Google Scholar]
  • 17. Chagnon P, Betard C, Robitaille Y, Cholette A, Gauvreau D (1995) Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. NeuroReport 6: 711–715. [DOI] [PubMed] [Google Scholar]
  • 18. Chang JW, Coleman PD, O'Banion MK (1996) Prostaglandin G/H synthase‐2 (cyclooxygenase‐2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 17: 801–808. [DOI] [PubMed] [Google Scholar]
  • 19. Cohen G, Werner P (1994) Free radicals, oxidative stress and neurodegeneration, In: Neurodegenerative Diseases, Calne DB, (Ed.), Chapter 10, pp 139–161, W B. Saunders Co., Philadelphia , PA , USA . [Google Scholar]
  • 20. Colton CA, Gilbert DL (1987) Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223: 284–288. [DOI] [PubMed] [Google Scholar]
  • 21. Colton CA, Snell J, Chernyshev O, Gilbert DL (1994) Induction of superoxide anion and nitric oxide production in cultured microglia. Ann. NY Acad. Sci. 738: 54–63. [DOI] [PubMed] [Google Scholar]
  • 22. Connor JR, Menzies SL, Martin SM St., Mufson EJ (1992a) A histochemical study of iron, transferrin and ferritin in Alzheimer's diseased brains. J Neurosci Res 31: 75–83. [DOI] [PubMed] [Google Scholar]
  • 23. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992b) Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci Res 31: 327–335. [DOI] [PubMed] [Google Scholar]
  • 24. Connor JR, Menzies SL (1995) Cellular management of iron in the brain. J Neurol Sci 134: 33–44. [DOI] [PubMed] [Google Scholar]
  • 25. Cornett CR, Markesbery W.R.W.D. (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19: 339–346. [PubMed] [Google Scholar]
  • 26. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689–695. [DOI] [PubMed] [Google Scholar]
  • 27. Danielson UH, Esterbauer H, Mannervik B (1987) Structure‐activity relationships of 4‐hydroxyalkenals in the conjugation catalysed by mammalian glutathione transferases. Biochem J. 247: 707–713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Davies KJ (1995) Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 61: 1–31. [DOI] [PubMed] [Google Scholar]
  • 29. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol Sci 143:137–142. [DOI] [PubMed] [Google Scholar]
  • 30. Ehmann WD, Markesbery WR, Alauddin M, Hossain TIM, Brubaker EH (1986) Brain trace elements in Alzheimer's disease. Neurotoxicology 7: 197–206. [PubMed] [Google Scholar]
  • 31. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4‐ hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81–128. [DOI] [PubMed] [Google Scholar]
  • 32. Evans PH (1993) Free radicals in brain metabolism and pathology. Br Med Bull 49: 577–587. [DOI] [PubMed] [Google Scholar]
  • 33. Fleming J, Joshi JG, Ferritin (1987) Isolation of aluminum ferritin complex from brain. Proc Natl Acad Sci USA 84: 7866–7870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Gabbita SP, Lovell MA, Markesbery WR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034–2040. [DOI] [PubMed] [Google Scholar]
  • 35. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Viteck MP, Gajdusek DC (1989) Interleukin‐1 regulates synthesis of amyloid beta‐protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86: 7606–7610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31: 286–292. [DOI] [PubMed] [Google Scholar]
  • 37. Good PF, Werner P, Hsu A, Olanow CW, Perl DP (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149: 21–28. [PMC free article] [PubMed] [Google Scholar]
  • 38. Grundke‐lqbal I, Fleming J, Tung Y‐C, Lassmann H, Iqbal K, Joshi JG (1990) Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81:105–110. [DOI] [PubMed] [Google Scholar]
  • 39. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64(3): 1216–1223. [DOI] [PubMed] [Google Scholar]
  • 40. Hajimohammadreza I, Brammer M (1990) Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci Lett 112: 333–337. [DOI] [PubMed] [Google Scholar]
  • 41. Hall ED, Braughler JM (1989) Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 6: 303–313. [DOI] [PubMed] [Google Scholar]
  • 42. Halliwell B, Gutteridge JMC (1989) Free Radicals in Biology and Medicine, 2nd Edition, Clarendon Press: Oxford University Press, New York , NY , USA . [Google Scholar]
  • 43. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM (1995) Direct evidence of oxidative injury produced by the Alzheimer's beta‐amyloid peptide (1–40) in cultured hippocampal neurons. Exp Neurol 131: 193–202. [DOI] [PubMed] [Google Scholar]
  • 44. Hensley K, Carney JM, Hall N, Shaus W, Butterfield DA (1994a) Electron paramagnetic resonance investigations of free radical induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Radic. Biol. Med. 17:321–331. [DOI] [PubMed] [Google Scholar]
  • 45. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA (1994a) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146–2156 1995. [DOI] [PubMed] [Google Scholar]
  • 46. Hermon M, Cairns N, Egly JM, Fery A, Labudova O, Lubec G (1998) Expression of DNA excision‐repair‐cross‐complementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease. Neurosci Lett 251: 45–48. [DOI] [PubMed] [Google Scholar]
  • 47. Hirai K, Smith MA, Wade R, Perry G (1998) Vulnerable neurons in Alzheimer disease accumulate mitochondrial DNA with the common 5KB deletion. J Neuropathol Exp Neurol 57: 511. [Google Scholar]
  • 48. Hunt JV, Smith CC, Wolff SP (1990) Autooxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420–1424. [DOI] [PubMed] [Google Scholar]
  • 49. Hunt JV, Wolff SP (1991) Oxidative glycation and free radical productions: a causal mechanism of diabetic complications. Free Radic Res Commun 12–13: 115–123. [DOI] [PubMed] [Google Scholar]
  • 50. Hunt JV, Bottoms MA, Mitchinson MJ (1993) Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein‐glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. Biochem J 291: 529–535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Jagust WJ (1998) Neuroimaging of dementing disorders. In: Neuropathology of Dementing Disorders, Markesbery WR (ed.) Chapter 2, pp. 25–55, Arnold: London , UK . [Google Scholar]
  • 52. Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O, McGeer PL (1996) Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 712: 122–126. [DOI] [PubMed] [Google Scholar]
  • 53. Kato K, Kurobe N, Suzuki R, Morishita R, Asano T, Sato T, Inagaki T (1991) Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease. J Mol Neurosci 3: 95–99. [DOI] [PubMed] [Google Scholar]
  • 54. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid ß‐ peptide: role of the lipid peroxidation product 4‐hydroxynonenal. J Neurochem 69: 273–284. [DOI] [PubMed] [Google Scholar]
  • 55. Kennard ML, Feldman H, Yamada T, Jefferies WA (1996) Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 2: 1230–1235. [DOI] [PubMed] [Google Scholar]
  • 56. Kish SJ, Morito CL, Hornykiewicz O (1986) Brain glutathione peroxidase in neurodegenerative disorders. Neurochem Pathol 4: 23–28. [DOI] [PubMed] [Google Scholar]
  • 57. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, Distefano LM, Nobrega JN (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59: 776–779. [DOI] [PubMed] [Google Scholar]
  • 58. Klegeris A, Walker DG, McGeer PL (1994) Activation of macrophages by Alzheimer ‐amyloid peptide. Biochem Biophys Res Commun 199: 984–991. [DOI] [PubMed] [Google Scholar]
  • 59. Kruman I, Bruce‐Keller AJ, Bredesen D, Waeg G, Mattson MP (1997) Evidence that 4‐hydroxynonenal mediates oxidative stress‐ induced neuronal apoptosis. J Neurosci 17: 5089–5100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid‐reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594–1601. [DOI] [PubMed] [Google Scholar]
  • 61. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4‐ hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457–461. [DOI] [PubMed] [Google Scholar]
  • 62. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998a) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47–52. [DOI] [PubMed] [Google Scholar]
  • 63. Lovell MA, Markesbery WR (1998b) Decreased glutathione transferase in brain and ventricular fluid in Alzheimer's disease. Neurology, in press. [DOI] [PubMed] [Google Scholar]
  • 64. Lovell MA, Gabbita SP, Markesbery WR (1998c) Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem, in press. [DOI] [PubMed] [Google Scholar]
  • 65. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brains from patients with Alzheimer's disease. J Neurochem 68: 2061–2069. [DOI] [PubMed] [Google Scholar]
  • 66. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150: 40–44. [DOI] [PubMed] [Google Scholar]
  • 67. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997a) A role for 4‐hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid (β‐peptide. J Neurochem 68: 255–264. [DOI] [PubMed] [Google Scholar]
  • 68. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997b) Amyloid (β‐ peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17: 1046–1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Markesbery WR, Lovell MA (1998) Four‐hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33–36. [DOI] [PubMed] [Google Scholar]
  • 70. Marklund SL, Adolfsson R, Gottfries CG, Winblad B (1985) Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 67: 319–325. [DOI] [PubMed] [Google Scholar]
  • 71. Marietta MA (1993) Nitric oxide synthase structure and mechanism. J Biol Chem 268: 12231–12234. [PubMed] [Google Scholar]
  • 72. Mattson MP, Lovell MA, Furukawa K, Markesbery WR (1995) Neurotrophic factors attenuate glutamate‐induced accumulation of peroxides, elevation of intracellular CA2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65:1740–1751. [DOI] [PubMed] [Google Scholar]
  • 73. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21 (2): 195–218. [DOI] [PubMed] [Google Scholar]
  • 74. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti‐inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425–432. [DOI] [PubMed] [Google Scholar]
  • 75. Mclntosh LJ, Trush MA, Troncoso JC (1997) Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical‐mediated processes. Free Radic Biol Med 23: 183–190. [DOI] [PubMed] [Google Scholar]
  • 76. McMillian M, Kong LY, Sawin SM, Wilson B, Das K, Hudson P, Hong JS, Bing G (1995) Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem Biophys Res Commun 215: 572–577. [DOI] [PubMed] [Google Scholar]
  • 77. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF (1993) Oxidative damage to mitochondrial DNA shows marked age‐ dependent increases in human brain. Ann Neurol 34: 609–616. [DOI] [PubMed] [Google Scholar]
  • 78. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747–751. [DOI] [PubMed] [Google Scholar]
  • 79. Miatto O, Gonzalez RG, Buonanno F, Growdon JH (1986) In vitro 31 p NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can J Neurol Sci. 13: 535–539. [DOI] [PubMed] [Google Scholar]
  • 80. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG (1996a) E‐4‐ hydroxy‐2‐nonenal is cytotoxic and cross‐links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 148: 89–93. [PMC free article] [PubMed] [Google Scholar]
  • 81. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ (1997) 4‐hydroxy‐ 2‐nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56(8): 866–871. [DOI] [PubMed] [Google Scholar]
  • 82. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998a) Cerebrospinal fluid F2 isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44: 410–413. [DOI] [PubMed] [Google Scholar]
  • 83. Montine KS, Recch E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ (1998b) Distribution of reducible 4‐hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57: 415–425. [DOI] [PubMed] [Google Scholar]
  • 84. Morrow JD, Roberts LJ (1997) The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1–21. [DOI] [PubMed] [Google Scholar]
  • 85. Mullaart E, Boerrigter ME, Swabb RR, Vijg J (1990) Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11: 169–173. [DOI] [PubMed] [Google Scholar]
  • 86. Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63: 2179–2184. [DOI] [PubMed] [Google Scholar]
  • 87. Münch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Rev 23: 134–143. [DOI] [PubMed] [Google Scholar]
  • 88. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y (1997) Association of transferrin C2 allele with late‐onset Alzheimer's disease. Hum Genet 101: 126–129. [DOI] [PubMed] [Google Scholar]
  • 89. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:(21)14998–15004. [PubMed] [Google Scholar]
  • 90. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 89: 1671–1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD (1996) Interleukin 1‐B induces prostaglandin G/H synthase‐2 (cyclooxygenase‐2) in primary murine astrocyte cultures. J Neurochem 66: 2532–2546. [DOI] [PubMed] [Google Scholar]
  • 92. Pappolla MA, Omar RA, Kim KS, Robakis NK (1992) Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 140: 621–628. [PMC free article] [PubMed] [Google Scholar]
  • 93. Parker WD, Parks JK, Filley CM, Kleinschmidt‐DeMasters BK (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44: 1090–1096. [DOI] [PubMed] [Google Scholar]
  • 94. Parker WD, Parks JK (1995) Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45: 482–486. [DOI] [PubMed] [Google Scholar]
  • 95. Partridge RS, Monroe SM, Parks JK, Johnson K, Parker WD, Eaton GR, Eaton SS (1994) Spin trapping of azidyl and hydroxyl radicals in azide‐inhibited rat brain submitochondrial particles. Arch Biochem Biophys 310: 210–217. [DOI] [PubMed] [Google Scholar]
  • 96. Pettigrew JW, Moossy J, Withers G, McKeag D, Panchalingam K (1988) 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J. Neuropathol Exp Neurol 47: 235–248. [DOI] [PubMed] [Google Scholar]
  • 97. Prasad MR, Lovell MA, Yatkin M, Dhillon H, Markesbery WR (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23: 81–88. [DOI] [PubMed] [Google Scholar]
  • 98. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase‐1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65: 1399–1402. [DOI] [PubMed] [Google Scholar]
  • 99. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752–758. [DOI] [PubMed] [Google Scholar]
  • 100. Richardson JS (1993) Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 695: 73–76. [DOI] [PubMed] [Google Scholar]
  • 101. Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD (1998) Formation of isoprostane‐like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 22: 13605–13612. [DOI] [PubMed] [Google Scholar]
  • 102. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609–1611. [DOI] [PubMed] [Google Scholar]
  • 103. Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med 47: 387–400. [DOI] [PubMed] [Google Scholar]
  • 104. Samudralwar DL, DiPrete CC, Ni BF, Ehmann WD, Markesbery WR (1995) Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 130: 139–145. [DOI] [PubMed] [Google Scholar]
  • 105. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thai LJ (1997) A controlled trial of selegiline, alpha‐tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336: 1216–1222. [DOI] [PubMed] [Google Scholar]
  • 106. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4‐ Hydroxynonenal‐derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092–2097. [DOI] [PubMed] [Google Scholar]
  • 107. Schipper HM, Cisse S, Stopa EG (1995) Expression of heme oxygenase‐1 in he senescent and Alzheimer‐diseased brain. Ann Neurol 37: 758–768. [DOI] [PubMed] [Google Scholar]
  • 108. Schmidt A. M., Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial surface. J Biol Chem 267(21): 14987–14997. [PubMed] [Google Scholar]
  • 109. Simonian NA, Hyman BT (1993) Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 52: 580–585. [PubMed] [Google Scholar]
  • 110. Simonian NA, Hyman BT (1994) Functional alterations in Alzheimer's disease: selective loss of mitochondrial‐encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol 53:508–512. [DOI] [PubMed] [Google Scholar]
  • 111. Smale G, Nichols NR, Brady DR, Finche CE, Horton WE (1995) Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225–230. [DOI] [PubMed] [Google Scholar]
  • 112. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, LaRue A, Adamson CF, Chang LEA (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273: 942–947. [PubMed] [Google Scholar]
  • 113. Smith CD, Carney JM, Starke‐Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc. Natl. Acad. Sci. USA 88: 10540–10543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Smith MA, Taneda S, Richey PL, Miyata S, Yan S‐D, Stern D, Sayre LM, Monnier VM, Perry G (1994a) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91: 5710–5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994b) Heme oxygenase‐1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42–47. [PMC free article] [PubMed] [Google Scholar]
  • 116. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18:172–176. [DOI] [PubMed] [Google Scholar]
  • 117. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382: 120–121. [DOI] [PubMed] [Google Scholar]
  • 118. Smith MA, Harris PLR, Sayre LM, Perry G (1997a) Iron accumulation in Alzheimer disease is a source of redox‐generated free radicals. Proc Natl Acad Sci USA 94: 9866–9868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Smith MA, Richey‐Harris P, Sayre LM, Beckman JS, Perry G (1997b) Widespread peroxynitrite‐mediated damage in Alzheimer's disease. J Neurosci 17: 2653–2657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120. Sohal RS (1997) Role of mitochondria and oxidative stress in the aging process. In: Mitochondria and Free Radicals in Neurodegeneration Diseases, Beal MF, Howell N, Bodis‐Wollner I, (Eds.), Chapter 5, pp 91–107, Wiley‐Liss, Inc: New York , NY , USA . [Google Scholar]
  • 121. Stadelmann C, Bruck W, Bancher C, Jellinger K, Lassman H (1998) Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathol Exp Neurol 57:456–464. [DOI] [PubMed] [Google Scholar]
  • 122. Stadtman ER (1992) Protein oxidation and aging. Science 257:1220–1224. [DOI] [PubMed] [Google Scholar]
  • 123. Su JH, Anderson AJ, Cummings BJ, Cotman CW (1994) Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport5: 2529–2533. [DOI] [PubMed]
  • 124. Su JH, Deng G, Cotman CW (1997) Neuronal DNA damage precedes tangle formation and is associated with up‐regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774:193–197. [DOI] [PubMed] [Google Scholar]
  • 125. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55: 342–345. [DOI] [PubMed] [Google Scholar]
  • 126. Svennerholm L, Gottfries CG (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early‐onset (type I) and demyelination in late‐onset form (type II). J. Neurochem. 62: 1039–1047. [DOI] [PubMed] [Google Scholar]
  • 127. Uchida H, Stadtman ER (1992) Modification of histidine residues in proteins by reaction with 4‐hydroxynonenal. Proc Natl Acad Sci USA 89: 4544–4589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol Toxicol 38: 97–120. [DOI] [PubMed] [Google Scholar]
  • 129. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91: 4766–4770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Wade R, Hirai K, Perry G, Smith MA (1998) Accumulation of 8‐hydroxyguanosine in neuronal cytoplasm indicates mitochondrial damage and radical production are early features of Alzheimer disease. J Neuropathol Exp Neurol 57: 511. [Google Scholar]
  • 131. Walker DG, Kim SU, McGeer PL (1995) Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 40: 478–493. [DOI] [PubMed] [Google Scholar]
  • 132. Yamabe T, Dhir G, Cowan EP, Wolf AL, Bergey GK, Krumholz A, Barry E, Hoffman PM, Dhib‐Jalbut S (1994) Cytokine‐gene expression in measles‐ infected adult human glial cells. J Neuroimmunol 49: 171–179. [DOI] [PubMed] [Google Scholar]
  • 133. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern D (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91: 7787–7791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid‐beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685–691. [DOI] [PubMed] [Google Scholar]
  • 135. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM (1997) Amyloid‐B peptide‐receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage‐colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci, USA 94: 5296–5301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136. Yatin SM, Aksenova M, Aksenova M, Markesbery WR, Aulick T, Butterfield DA (1998) Temporal relations between amyloid B‐peptide‐induced free radical oxidative stress and neuronal toxicity and neuronal defense responses. Submitted. [DOI] [PubMed]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES